PARP-1 (Poly[ADP-Ribose] Polymerase-1)

Overview

Journal Hypertension

Date 2018 Oct 26

PMID 30354832

Citations 5

Authors

Rheure Alves-Lopes

Rhian M Touyz

Affiliations

Soon will be listed here.

Citing Articles

Poly (ADP-ribose) Polymerase-1 modulations in the genesis of thrombosis.

Safdar R, Mishra A, Shah G, Ashraf M J Thromb Thrombolysis. 2024; 57(5):743-753.

PMID: 38787496 DOI: 10.1007/s11239-024-02974-3.

Role of PARP and TRPM2 in VEGF Inhibitor-Induced Vascular Dysfunction.

Neves K, Alves-Lopes R, Montezano A, Touyz R J Am Heart Assoc. 2023; 12(4):e027769.

PMID: 36802924 PMC: 10111475. DOI: 10.1161/JAHA.122.027769.

Tissue remodelling and increased DNA damage in patients with incompetent valves in chronic venous insufficiency.

Ortega M, Fraile-Martinez O, Garcia-Montero C, Pekarek L, Alvarez-Mon M, Guijarro L J Cell Mol Med. 2021; 25(16):7878-7889.

PMID: 34148301 PMC: 8358866. DOI: 10.1111/jcmm.16711.

Contributions of PARP-1 rs1136410 C>T polymorphism to the development of cancer.

Li H, Zha Y, Du F, Liu J, Li X, Zhao X J Cell Mol Med. 2020; 24(24):14639-14644.

PMID: 33108038 PMC: 7753995. DOI: 10.1111/jcmm.16027.

Poly(ADP-ribose) polymerase inhibition: past, present and future.

Curtin N, Szabo C Nat Rev Drug Discov. 2020; 19(10):711-736.

PMID: 32884152 DOI: 10.1038/s41573-020-0076-6.

References

Berger N, Besson V, Boulares A, Burkle A, Chiarugi A, Clark R . Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br J Pharmacol. 2017; 175(2):192-222. PMC: 5758399. DOI: 10.1111/bph.13748. View

Oumouna-Benachour K, Hans C, Suzuki Y, Naura A, Datta R, Belmadani S . Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell.... Circulation. 2007; 115(18):2442-50. DOI: 10.1161/CIRCULATIONAHA.106.668756. View

Ray Chaudhuri A, Nussenzweig A . The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017; 18(10):610-621. PMC: 6591728. DOI: 10.1038/nrm.2017.53. View

Tsui J . Experimental models of abdominal aortic aneurysms. Open Cardiovasc Med J. 2011; 4:221-30. PMC: 3026392. DOI: 10.2174/1874192401004010221. View

Luo X, Kraus W . On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev. 2012; 26(5):417-32. PMC: 3305980. DOI: 10.1101/gad.183509.111. View

Szabo C, Pacher P, Zsengeller Z, Vaslin A, Komjati K, Benko R . Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation. Mol Med. 2004; 10(1-6):28-35. PMC: 1431352. DOI: 10.2119/2004-00001.szabo. View

Sun Z . Abdominal aortic aneurysm: Treatment options, image visualizations and follow-up procedures. J Geriatr Cardiol. 2012; 9(1):49-60. PMC: 3390098. DOI: 10.3724/SP.J.1263.2012.00049. View

Benko R, Pacher P, Vaslin A, Kollai M, Szabo C . Restoration of the endothelial function in the aortic rings of apolipoprotein E deficient mice by pharmacological inhibition of the nuclear enzyme poly(ADP-ribose) polymerase. Life Sci. 2004; 75(10):1255-61. DOI: 10.1016/j.lfs.2004.04.007. View

Gupte R, Liu Z, Kraus W . PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Genes Dev. 2017; 31(2):101-126. PMC: 5322727. DOI: 10.1101/gad.291518.116. View

10.

Dawson J, Choke E, Sayed S, Cockerill G, Loftus I, Thompson M . Pharmacotherapy of abdominal aortic aneurysms. Curr Vasc Pharmacol. 2006; 4(2):129-49. DOI: 10.2174/157016106776359817. View

11.

Yu P, Xue X, Zhang J, Hu X, Wu Y, Jiang L . Identification of the ADPR binding pocket in the NUDT9 homology domain of TRPM2. J Gen Physiol. 2017; 149(2):219-235. PMC: 5299621. DOI: 10.1085/jgp.201611675. View

12.

Wang Y, Wang L, Zhang F, Zhang C, Deng S, Wang R . Inhibition of PARP prevents angiotensin II-induced aortic fibrosis in rats. Int J Cardiol. 2012; 167(5):2285-93. DOI: 10.1016/j.ijcard.2012.06.050. View

13.

Guzik T, Touyz R . Oxidative Stress, Inflammation, and Vascular Aging in Hypertension. Hypertension. 2017; 70(4):660-667. DOI: 10.1161/HYPERTENSIONAHA.117.07802. View

14.

Wang Y, Krishna S, Golledge J . The calcium chloride-induced rodent model of abdominal aortic aneurysm. Atherosclerosis. 2012; 226(1):29-39. DOI: 10.1016/j.atherosclerosis.2012.09.010. View

15.

Eros K, Magyar K, Deres L, Skazel A, Riba A, Vamos Z . Chronic PARP-1 inhibition reduces carotid vessel remodeling and oxidative damage of the dorsal hippocampus in spontaneously hypertensive rats. PLoS One. 2017; 12(3):e0174401. PMC: 5365133. DOI: 10.1371/journal.pone.0174401. View

16.

Hu C, Zhu K, Li J, Wang C, Lai L . Molecular targets in aortic aneurysm for establishing novel management paradigms. J Thorac Dis. 2017; 9(11):4708-4722. PMC: 5721044. DOI: 10.21037/jtd.2017.10.63. View

17.

Liang E, Bai W, Wang H, Zhang J, Zhang F, Ma Y . PARP-1 (Poly[ADP-Ribose] Polymerase 1) Inhibition Protects From Ang II (Angiotensin II)-Induced Abdominal Aortic Aneurysm in Mice. Hypertension. 2018; 72(5):1189-1199. DOI: 10.1161/HYPERTENSIONAHA.118.11184. View

18.

Henning R, Bourgeois M, Harbison R . Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders. Cardiovasc Toxicol. 2018; 18(6):493-506. DOI: 10.1007/s12012-018-9462-2. View